BRACCO IMAGING SPA

Their core work

Bracco Imaging is a major Italian diagnostic imaging company specializing in contrast agents and imaging solutions for medical diagnostics. Within H2020, they contributed industry expertise in advanced MRI and CT imaging techniques, particularly for oncology and cardiovascular applications. Their work spans development of molecular imaging biomarkers (GlucoCEST for cancer detection) and next-generation spectral CT for vascular disease diagnosis. They also support doctoral training in life sciences, reflecting their commitment to building research capacity alongside product development.

What they specialise in

How they've shifted over time

All three H2020 projects launched in 2016, making temporal evolution difficult to track precisely. However, keyword analysis shows a shift from broad life sciences and biomaterial training (INCIPIT) toward highly specific clinical imaging applications — cancer biomarkers, glucose metabolism imaging, and advanced MRI/CT modalities. This suggests Bracco used H2020 to move from general capacity-building toward targeted translational imaging research with direct clinical relevance.

Bracco is deepening its focus on molecular and metabolic imaging for oncology and cardiovascular diagnostics, moving toward clinically translatable imaging biomarkers.

How they like to work

Bracco consistently participates as a partner rather than leading consortia, reflecting a large-industry role of contributing proprietary imaging expertise and infrastructure to research-driven projects. With 37 unique partners across 12 countries, they engage in broad European consortia rather than small bilateral collaborations. This pattern suggests they are a reliable industry partner who brings commercial imaging know-how and clinical translation capacity without seeking project leadership overhead.

Bracco has collaborated with 37 distinct partners across 12 European countries, indicating a well-connected position within the medical imaging research community. Their network spans universities, hospitals, and research institutes working on advanced diagnostic technologies.

What sets them apart

Bracco brings something rare to EU consortia: a large commercial imaging company with direct experience in contrast agents and diagnostic products, bridging the gap between academic imaging research and clinical-commercial deployment. Unlike university labs that develop techniques in isolation, Bracco can validate imaging methods against real product development pipelines. For consortium builders, they offer industry-grade imaging infrastructure and a pathway toward market translation that most academic partners cannot provide.

Highlights from their portfolio

• GLINT
  Largest funded project (EUR 645,250) combining MRI physics with cancer metabolism — a technically ambitious approach to tumour detection via glucose imaging.
• SPCCT
  Addresses next-generation CT technology (spectral photon counting) for two major disease areas — cardiovascular and neurovascular — with strong clinical translation potential.